Regeneron Pharmaceuticals Inc (REGN) Raised to Strong-Buy at Vetr Inc.

Vetr upgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research note released on Wednesday. They currently have $475.44 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. Evercore ISI set a $421.00 price objective on Regeneron Pharmaceuticals and gave the stock a hold rating in a report on Sunday, January 8th. Leerink Swann set a $448.00 price objective on Regeneron Pharmaceuticals and gave the stock a buy rating in a report on Saturday, February 11th. Chardan Capital raised Regeneron Pharmaceuticals from a sell rating to a neutral rating and upped their price objective for the stock from $300.00 to $350.00 in a report on Monday, December 12th. BTIG Research reaffirmed a neutral rating on shares of Regeneron Pharmaceuticals in a report on Thursday, November 17th. Finally, Wells Fargo & Co reaffirmed a market perform rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, January 10th. Fourteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of Hold and an average price target of $434.97.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 380.00 on Wednesday. The stock’s 50 day moving average price is $371.86 and its 200-day moving average price is $379.60. The stock has a market cap of $40.08 billion, a P/E ratio of 49.36 and a beta of 1.44. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $452.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The firm had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.30 billion. During the same quarter in the prior year, the business earned $2.83 EPS. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $12.95 earnings per share for the current year.

Your IP Address:

In other news, major shareholder Sanofi bought 87,298 shares of the stock in a transaction on Wednesday, January 11th. The stock was purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.40% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $291,560,000. WFG Advisors LP boosted its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,415 shares during the period. I.G. Investment Management LTD. boosted its position in Regeneron Pharmaceuticals by 560.4% in the fourth quarter. I.G. Investment Management LTD. now owns 5,600 shares of the biopharmaceutical company’s stock worth $2,056,000 after buying an additional 4,752 shares during the period. Thrivent Financial for Lutherans boosted its position in Regeneron Pharmaceuticals by 6.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,620 shares of the biopharmaceutical company’s stock worth $962,000 after buying an additional 160 shares during the period. Finally, IFM Investors Pty Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $373,000. Hedge funds and other institutional investors own 68.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

To view Vetr’s full report, visit Vetr’s official website.

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-raised-to-strong-buy-at-vetr-inc/1708947.html

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *